Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients

Table 1

Patient demographics and clinical characteristics.

Subjects characteristics	PT0,	PT1,	HD,	value
Age, years, mean (SD)	71.27 (5.51)	71.27 (5.51)	67.0 (9.4)
Male, (%)	8 (72.72)	8 (72.72)	9 (81.81)
Former smokers, (%)	9 (81.8)	9 (81.8)	8 (72.72)
FVC, ml, mean (SD)	2343.6 (777.88)	2385.45 (801.51)		0.6328^§
FVC, % predicted, mean (SD)	81.04 (26.95)	77.90 (24.49)		0.1813^§
FEV1/FVC ratio, %, mean (SD)	92.81 (4.43)	91.66 (6.66)		0.7161^§
DLCO, % predicted, mean (SD)	54.17 (18.11)	56.1 (22.38)		0.5770^§

PT0, Pirfenidone T0, which refers to untreated patients just diagnosticated with IPF; PT1, Pirfenidone T1, which refers to IPF patients treated with Pirfenidone for 24 weeks; HD, healthy donors, which refers to healthy blood donors; FVC, forced vital capacity; FEV₁, forced expiratory volume₁; DLCO, carbon monoxide diffusing lung capacity. values were determined by paired t-test (PT0 versus PT1), unpaired t-test (HD versus PT0/PT1), and ^#Chi-square (HD versus PT0/PT1).